Chronic Idiopathic Constipation (CIC): Optimizing Pharmacotherapeutic Management Strategies

Chronic Idiopathic Constipation (CIC) discusses conventional therapies: bulking agents, softeners, stimulants, osmotics; recent additions and investigational agents: prucalopride, plecanatide, linaclotide, lubiprostone; non-pharmacologic therapies and their place relative to pharmacotherapy: dietary, ...

Chronic Idiopathic Constipation (CIC) discusses conventional therapies: bulking agents, softeners, stimulants, osmotics; recent additions and investigational agents: prucalopride, plecanatide, linaclotide, lubiprostone; non-pharmacologic therapies and their place relative to pharmacotherapy: dietary, mechanical, behavioral, and surgical interventions; biofeedback; and clinical pearls and difficult-to-treat cases.After reviewing Chronic Idiopathic Constipation (CIC), you will be able to: • Describe the pathophysiology of chronic idiopathic constipation • Describe the benefits and risks of pharmacotherapy for chronic idiopathic constipation and take them into account when formulating a treatment plan for different patients • Formulate an evidence-based treatment plan for a variety of patients with chronic idiopathic constipation. • Recommend therapy changes in patients with chronic idiopathic constipation who do not respond to a previously prescribed treatmentTarget Audience: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with chronic idiopathic constipation.

---

Write the first review

Resource tags